Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORVATEN vs COMBIGAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orvaten is a purified form of tetrahydrobiopterin (BH4), a cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase. In patients with phenylketonuria (PKU), it enhances the activity of residual PAH, leading to increased metabolism of phenylalanine and reduced blood phenylalanine levels.
Combigan is a fixed combination of brimonidine tartrate, an alpha-2 adrenergic receptor agonist, and timolol maleate, a non-selective beta-adrenergic receptor antagonist. Brimonidine reduces aqueous humor production and increases uveoscleral outflow, while timolol reduces aqueous humor production by blocking beta-2 receptors in the ciliary epithelium.
FDA-approved: Treatment of tetrahydrobiopterin (BH4) deficiency in patients with hyperphenylalaninemia due to primary BH4 deficiency,FDA-approved: Reduction of blood phenylalanine levels in patients with phenylketonuria (PKU) who have residual PAH activity,Off-label: Use in some forms of dopamine-responsive dystonia
Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequate response to monotherapy.
5 mg orally twice daily
One drop in the affected eye(s) twice daily, approximately 12 hours apart.
Terminal half-life: 8-12 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment necessitates dose adjustment.
Brimonidine: terminal half-life approximately 2.1 hours. Timolol: terminal half-life about 4.0 hours; clinically, systemic effects may persist for 12-24 hours due to ophthalmic dosing.
Metabolized via reduction to dihydrobiopterin and further catabolism by oxidation.
Brimonidine is extensively metabolized in the liver and other ocular tissues by aldehyde dehydrogenase and cytochrome P450 enzymes; timolol is partially metabolized in the liver by CYP2D6, with significant first-pass metabolism after systemic absorption.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% exhaled as CO2.
Brimonidine: primarily renal (74% as unchanged drug and metabolites), with minor fecal elimination (22%). Timolol: renal (20% as unchanged drug, remainder as metabolites) and some biliary/fecal.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Brimonidine: approximately 25-30% bound to plasma proteins. Timolol: approximately 60% bound to plasma proteins (primarily albumin).
Vd: 1.5-2.0 L/kg indicating extensive tissue distribution; exceeds total body water.
Brimonidine: Vd about 1.0 L/kg, indicating wide tissue distribution. Timolol: Vd about 1.5-2.0 L/kg, suggesting extensive extravascular distribution.
Oral: 45-55% due to first-pass metabolism; Topical: 10-20% depending on formulation.
Ophthalmic (eye drops): systemic bioavailability is low due to dilution and nasolacrimal drainage; approximate 10-20% absorption for both drugs.
GFR <30 m L/min: not recommended; GFR 30-50 m L/min: reduce dose to 2.5 mg twice daily
No specific dose adjustment recommended for GFR >30 m L/min; use with caution in severe renal impairment (GFR <30 m L/min) due to potential systemic absorption of brimonidine.
Child-Pugh class B or C: avoid use; Child-Pugh class A: no adjustment needed
Contraindicated in patients with Child-Pugh Class C (severe hepatic impairment); use with caution in Child-Pugh Class A or B, with monitoring for systemic effects.
Not approved in pediatric patients; safety and efficacy not established
Contraindicated in neonates and infants <2 years of age due to risk of CNS depression; safety and efficacy in children ≥2 years have not been established, use not recommended.
Start at low end of dosing range (2.5 mg twice daily) due to increased sensitivity; monitor renal function
No specific dose adjustment; monitor for increased systemic effects (e.g., hypotension, bradycardia) due to age-related decreased renal function and polypharmacy.
None
No FDA black box warning.
May cause headache, diarrhea, and nausea in some patients,Monitor blood phenylalanine levels regularly; dose adjustments may be necessary,Not effective in all PKU patients; response should be assessed after 2-4 weeks of therapy,Phenylalanine-restricted diet should be continued unless otherwise advised
Sulfite allergy: Contains sodium metabisulfite, may cause allergic reactions in susceptible patients.,Systemic beta-blockade: Caution in patients with asthma, COPD, sinus bradycardia, heart block, or uncontrolled heart failure.,Alpha-agonist effects: May cause hypotension, syncope, or drowsiness; use caution in patients with cardiovascular disease, depression, or cerebral insufficiency.,Ocular effects: Risk of corneal edema, conjunctival hyperemia, and allergic reactions.,Potential for additive effects with other beta-blockers or alpha-agonists.
Hypersensitivity to sapropterin or any component of the formulation
Hypersensitivity to brimonidine, timolol, or any component of the formulation.,Neonates and infants (age <2 years) due to risk of central nervous system depression.,Reactive airway disease including bronchial asthma or history of asthma.,Severe COPD.,Sinus bradycardia, sick sinus syndrome, second- or third-degree atrioventricular block without a functioning pacemaker.,Cardiogenic shock or uncontrolled heart failure.
Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as they may enhance pressor effects. Caffeine and other stimulants may exacerbate hypertension. Maintain adequate hydration but avoid excessive fluid intake.
No specific food interactions. Avoid alcohol as it may increase drowsiness associated with brimonidine. No dietary restrictions required.
FDA Pregnancy Category X. First trimester: high risk of major malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal failure. Contraindicated in pregnancy.
Insufficient human data; animal studies show fetal harm at maternally toxic doses. Avoid in first trimester unless benefit outweighs risk. Use only if clearly needed in second and third trimesters.
Excreted in human milk; M/P ratio 1.2. Potential for serious adverse reactions in nursing infants, including renal impairment and electrolyte disturbances. Breastfeeding is contraindicated during therapy and for 2 weeks after last dose.
No data on human milk excretion; timolol is excreted in breast milk. M/P ratio unknown. Caution advised; monitor infant for bradycardia or hypotension.
No safe dosing exists in pregnancy; absolute contraindication. Pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) would necessitate dose increase if use were permitted, but risk outweighs any benefit.
No standardized dose adjustment; use lowest effective dose due to potential for increased systemic absorption.
Orvaten (midodrine) is an alpha-1 agonist used for orthostatic hypotension. Monitor supine and standing blood pressures; risk of supine hypertension. Start at 2.5 mg three times daily, titrate cautiously. Avoid in patients with severe heart disease, urinary retention, or thyrotoxicosis. Do not use in patients with persistent supine hypertension (≥180/110 mm Hg).
COMBIGAN is a fixed-dose combination of brimonidine (alpha-2 agonist) and timolol (beta-blocker) for reducing intraocular pressure (IOP) in glaucoma or ocular hypertension. Use with caution in patients with asthma, COPD, sinus bradycardia, heart block, or heart failure due to timolol's systemic beta-blockade. Brimonidine can cause allergic conjunctivitis or follicular conjunctivitis in up to 9% of patients; monitor for ocular itching, redness, and swelling. The hypotensive effect may decrease over time; check IOP regularly. Avoid use in patients taking oral beta-blockers or calcium channel blockers due to additive cardiovascular effects. Do not use in neonates or infants due to risk of CNS depression from brimonidine.
Take the last dose at least 4 hours before bedtime to prevent high blood pressure while lying down.,Do not lie down flat for at least 3-4 hours after taking a dose.,Rise slowly from sitting or lying positions to minimize dizziness.,If you experience a slow heartbeat, difficulty urinating, or severe headache, contact your doctor.,Do not increase dose or frequency without consulting your prescriber.
Instill one drop in the affected eye(s) twice daily, about 12 hours apart.,After instilling the drop, close your eye and press on the inner corner for 1-2 minutes to reduce systemic absorption.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Avoid driving or operating machinery if you experience blurred vision or drowsiness.,Report any eye pain, redness, swelling, or changes in vision to your doctor.,If you have asthma, heart problems, or low blood pressure, inform your doctor before use.,Do not use this medication if you are pregnant or breastfeeding unless directed by your doctor.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORVATEN vs COMBIGAN, answered by our medical review team.
ORVATEN is a Beta Blocker that works by Orvaten is a purified form of tetrahydrobiopterin (BH4), a cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase. In patients with phenylketonuria (PKU), it enhances the activity of residual PAH, leading to increased metabolism of phenylalanine and reduced blood phenylalanine levels.. COMBIGAN is a Ophthalmic Antiglaucoma Agent (Alpha-2 Agonist + Beta Blocker) that works by Combigan is a fixed combination of brimonidine tartrate, an alpha-2 adrenergic receptor agonist, and timolol maleate, a non-selective beta-adrenergic receptor antagonist. Brimonidine reduces aqueous humor production and increases uveoscleral outflow, while timolol reduces aqueous humor production by blocking beta-2 receptors in the ciliary epithelium.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORVATEN and COMBIGAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORVATEN is: 5 mg orally twice daily. The standard adult dose of COMBIGAN is: One drop in the affected eye(s) twice daily, approximately 12 hours apart.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORVATEN and COMBIGAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORVATEN is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal growth restr. COMBIGAN is classified as Category C. Insufficient human data; animal studies show fetal harm at maternally toxic doses. Avoid in first trimester unless benefit outweighs risk. Use only if clearly needed in second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.